Tirzepatide vs Retatrutide: Trial Results and Key Differences
Compare tirzepatide and investigational retatrutide: trial populations, weight-loss results, TRIUMPH studies and why separate trials cannot prove superiority.
Tirzepatide is an approved medicine; retatrutide remains investigational. Retatrutide has produced substantial weight loss in trials, but results from different studies do not establish which treatment would work better for one person. This guide separates access, study design and the numbers behind the comparison.
The differences at a glance
| Question | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| US access | Prescription products Mounjaro and Zepbound, with different labeled uses | Investigational; access through the sponsor's clinical trials |
| Research examples | SURMOUNT obesity trials and diabetes studies | Phase 2 obesity study; Phase 3 TRIUMPH and TRANSCEND programs |
| Can a trial dose be copied? | Treatment follows the specific product label and prescriber | There is no approved consumer dosing schedule |
Sources: Mounjaro prescribing information, Zepbound prescribing information and Lilly's retatrutide overview.
What the published obesity trials found
Two frequently quoted results come from different randomized trials:
| Study | Participants and follow-up | Selected result |
|---|---|---|
| SURMOUNT-1, tirzepatide | 2,539 adults with obesity or overweight and a complication, without diabetes; 72 weeks | Mean weight change at 15 mg was −20.9%, versus −3.1% with placebo |
| Phase 2 retatrutide study | 338 adults with obesity or overweight and a complication; 48 weeks | Mean weight change at 12 mg was −24.2%, versus −2.1% with placebo |
Sources: SURMOUNT-1, NEJM 2022 and retatrutide Phase 2, NEJM 2023.
Those figures are averages for selected trial groups, not promises for patients. Subtracting 20.9 from 24.2 does not produce a valid head-to-head treatment advantage. Follow-up, enrollment, dose escalation and handling of treatment discontinuation differ. A comparison should also state whether its estimate reflects remaining on treatment or a broader treatment-policy analysis.
A useful reading habit is to ask: same population, same follow-up, same outcome, same comparator? If one of these changes, a neat ranking may conceal a very different question. A higher dose expressed in milligrams also does not mean a directly comparable amount of pharmacological activity across molecules.
What TRIUMPH-1, -2, -3 and -4 actually study
| Trial | Population or focus |
|---|---|
| TRIUMPH-1 | Obesity or overweight without diabetes; includes specified osteoarthritis and sleep-apnea substudies |
| TRIUMPH-2 | Type 2 diabetes with obesity or overweight |
| TRIUMPH-3 | Severe obesity with established cardiovascular disease, with or without type 2 diabetes |
| TRIUMPH-4 | Obesity or overweight with knee osteoarthritis |
The population labels are supported by Lilly's program overview, the TRIUMPH-2 record and the TRIUMPH-4 record.
Lilly's July 2026 overview reports Phase 3 announcements across these programs. It distinguishes topline announcements from detailed results intended for later presentation and publication. A press release is a primary statement from the sponsor, but it does not supply all the methods and safety details available in a full trial report.
Correction: an earlier version of this article assigned knee osteoarthritis to TRIUMPH-2 and described TRIUMPH-4 as a maintenance/dose-response study. Those descriptions were incorrect and have been replaced.
Safety comparisons need comparable evidence
Gastrointestinal adverse effects were common in both the tirzepatide obesity trial and the retatrutide Phase 2 trial. The retatrutide study also reported dose-related heart-rate increases. These observations warrant attention, but they do not establish a reliable between-drug safety ranking.
Before comparing a safety percentage, check the event definition, exposure duration, dose group and number of people who stopped treatment. A study may capture nausea differently from another study; an adverse-event table cannot be read as a personalized risk score.
Our gallbladder evidence guide illustrates another distinction: pooled class evidence and product-specific safety information answer related but different questions.
Is retatrutide available, and can someone switch?
As checked September 15, 2026, Lilly identifies retatrutide as unapproved and available only through its clinical trials. It does not give an approved retail launch date or consumer dose-conversion schedule. Products sold online under that name are not equivalent to an approved prescription product. Sponsor's current access information.
If a current prescription is not meeting expectations, bring the response, side effects, access problems and goals to the prescriber. This is a different conversation from choosing a molecule using the largest percentage in a headline. Read our Mounjaro dose guide for label-based context and weight regain after treatment withdrawal for the longer-term evidence.
Sources and scope
This is an editorial comparison of linked labels, trial reports and sponsor records checked September 15, 2026. It replaces the previous cross-trial superiority framing and unsupported launch prediction. It is not a systematic review of every retatrutide result, a product recommendation or an independently physician-reviewed treatment guide.
Tags
More in GLP-1 Medications
Written By
Metabolic Science Editorial
Research and editorial content
Metabolic Science publishes educational articles with AI assistance. Our articles link to their sources and explain research limitations. They are not a substitute for care from a qualified health professional. No independent medical review is claimed.
Editorial Standards
This article follows our strict editorial guidelines. Content is prepared with AI assistance and includes source links. No independent medical review is claimed. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.